Entrectinib in patients with ROS1-positive NSCLC or NTRK fusion-positive solid tumors with CNS metastases
Authors
Paz-Ares, LDziadziuszko, R
Drilon, A
John, T
Krebs, Matthew G
Demetri, G
Shaw, A
Siena, S
Wolf, J
Farago, A
Simmons, B
Ye, C
Huang, X
Doebele, R
Affiliation
Hospital Universitario 12 de Octubre, Madrid/Issue Date
2019
Metadata
Show full item recordCitation
Paz-Ares L, Dziadziuszko R, Drilon A, John T, Krebs M, Demetri G, et al. MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases. Journal of Thoracic Oncology. 2019;14(10):S305.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2019.08.611Additional Links
https://dx.doi.org/10.1016/j.jtho.2019.08.611Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2019.08.611